| thiarabine (4-thio Ara-C) / Abeona Therap |
JPLSG-AML-20, JRCTs041210015: A clinical trial of risk-stratification and gemtuzumab ozogamicin combined post-induction chemotherapy for children with AML |
|
|
| Recruiting | 3 | 500 | Japan | thiarabine (4-thio Ara-C) - Abeona Therap, mitoxantrone - Generic mfg., methotrexate - Generic mfg., hydrocortisone - Generic mfg., Mylotarg (gemtuzumab ozogamicin) - UCB, PDL, Pfizer | National Center for Child Health and Development | Acute Myeloid Leukemia | | | | |
| rebisufligene etisparvovec (UX111) / Ultragenyx |
| Enrolling by invitation | 3 | 33 | Europe, US, RoW | No Investigational Product, Adjuvant Immunosuppression (IS) Therapy | Ultragenyx Pharmaceutical Inc, Abeona Therapeutics, Inc | Mucopolysaccharidosis III-A | 06/27 | 06/27 | | |
| Active, not recruiting | 2/3 | 28 | Europe, US, RoW | ABO-102, scAAV9.U1a.hSGSH, UX111, Adjuvant Immunosuppression (IS) Therapy | Ultragenyx Pharmaceutical Inc, Abeona Therapeutics, Inc | MPS IIIA, Sanfilippo Syndrome, Sanfilippo A, Mucopolysaccharidosis III | 01/25 | 01/25 | | |
2018-000504-42: Gene Therapy Clinical Trial for Mucopolysaccharidosis IIIA in patient with middle and advanced phases of the disease Ensayo Clínico de terapia génica para la Mucopolisacaridosis tipo IIIA en pacientes con enfermedad MPS IIIA media y avanzada |
|
|
| Not yet recruiting | 1/2 | 12 | Europe | scAAV9.U1A.SGSH, ABO-102, Suspension for injection | Abeona Therapeutics Inc, Abeona Therapeutics Inc | MPS IIIA is a devastating lysosomal storage disease, caused by a Nsulfoglucosamine sulfohydrolase gene defect. Infants with MPS IIIA appear normal at birth, but the disease is relentlessly progressive, withdeterioration of social and adaptive abilities, neurocognitive decline, and premature death. Death typically occurs by end of the second or beginning of the third decade. Quite importantly, there is no treatmentcurrently available for the disease. MPS IIIA es una enfermedad de depósito lisosomal, causada por un defecto genético de la enzima N-sulfoglucosamina sulfohidrolasa. Los niños parecen normales al nacer, pero la enfermedad es progresiva, conel deterioro de las habilidades sociales y de adaptación, la disminución neurocognitiva y la muerte prematura. La muerte se produce normalmente a finales de la segunda o principios de la tercera década. Es de destacar que no existe un tratamiento disponible actualmente para la enfermedad., Mucopolysaccharidosis type IIIA is a genetic disease in children, caused by the toxicity of an accumulation of substances in the body that generate a progressive deterioration. La mucopolisacaridosis tipo IIIA es una enfermedad genética en niños, causada por la toxicidad de un acúmulo de sustancias en el organismo que generan un deterioro progresivo., Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | | | | |
NCT06577532: Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Advanced Pancreatic Cancer |
|
|
| Recruiting | 1 | 56 | RoW | ABO2102, Toripalimab | Ruijin Hospital, Suzhou Abogen Biosciences Co., Ltd. | Pancreatic Neoplasms | 12/26 | 08/27 | | |
| ABO-101 / Abeona Therap |
NCT06096415: Safety and Efficacy of ABX-101 in Participants Aged 18 to 50 Years of Age With Moderate to Severe Traumatic Brain Injury |
|
|
| Not yet recruiting | 2a | 45 | NA | ABX-101 1mg, ABX-101 2mg | Abalonex, LLC | Traumatic Brain Injury, Cerebral Edema | 04/24 | 05/24 | | |
| prademagene zamikeracel (EB-101) / Abeona Therap |
VITAL, NCT03632265: Study of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa |
|
|
| Not yet recruiting | 3 | 15 | NA | EB-101, LEAES: LZRSE-Col7A1 Engineered Autologous Epidermal Sheets | Jean Yuh Tang, Abeona Therapeutics, Inc | Recessive Dystrophic Epidermolysis Bullosa | 09/20 | 03/21 | | |
NCT05725018: EB-101 Treatment for New and Previously Treated Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB) |
|
|
| Recruiting | 3 | 12 | US | EB-101 Surgical application of RDEB wounds, pz-cel | Abeona Therapeutics, Inc | Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, RDEB | 03/25 | 06/25 | | |
NCT01263379: Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa |
|
|
| Completed | 1/2 | 12 | US | LZRSE-Col7A1 Engineered Autologous Epidermal Sheets, LEAES | Abeona Therapeutics, Inc, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Stanford University | Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa | 03/22 | 03/22 | | |
NCT05708677: A Long-Term Extension Study for Participants Previously Treated With EB-101 for the Treatment of RDEB |
|
|
| Enrolling by invitation | N/A | 22 | US | EB-101, pz-cel | Abeona Therapeutics, Inc | RDEB | 02/36 | 08/36 | | |
| ABO-202 / Abeona Therap, Taysha Gene Therapies |
| No trials found |
| next-generation AIM AAV vector / Abeona Therap |
| No trials found |
| Fabry Disease Therapeutic / Abeona Therap |
| No trials found |
